Alternative medicine
Chelation Therapy (Non-Medical)
Non-medical chelation therapy is an alternative-medicine practice. Its proposed uses span several kinds of health concerns, but support is uneven: some findings come from trial-based research, while other rationales are theoretical.
Non-medical chelation therapy is an alternative-medicine practice that should be avoided; reported effects do not establish it as beneficial.
We do not advise this practice
It can cause harm.
Why it is not advised
Non-medical chelation is promoted for detoxification and cardiovascular or circulation benefits. Some human studies report lower urinary lead and improvements in circulation-related measures or wound healing in people with diabetes or vascular disease, but earlier randomized trials on heart disease did not agree on benefit. Findings in people therefore do not establish a general benefit from non-medical use; some proposed effects, such as reduced inflammation, have only been studied in animals.
Chelators can also bind essential minerals, disrupting calcium balance and potentially causing dangerous heart rhythm problems or seizures. Kidney toxicity and bleeding are additional concerns, with greater risk for people with kidney impairment, low calcium, or certain heart conditions. Safety in pregnancy and children has not been established; EDTA may affect mineral availability in a fetus or nursing infant, and non-medical use in children raises concerns about mineral depletion and growth.
Overview
Non-medical chelation therapy is an alternative-medicine practice. Its proposed uses span several kinds of health concerns, but support is uneven: some findings come from trial-based research, while other rationales are theoretical. Evidence for an individual proposed outcome does not establish that the practice benefits people generally or across the conditions for which it is considered. It is not advised as a non-medical practice. Overall, the broader picture remains unsettled, and evidence does not establish suitability for any particular person or condition.
Some research: 11 studies. Last checked Oct 7, 2026.
- 5
- human evidence
- 2
- eligible
- 6
- unclassified
- 3
- animal / null result
Claimed benefits
- Wound Healing AccelerationMedium · RCT
- Detoxification SupportLow · RCT
- Blood Pressure SupportLow · RCT
1 of 4 flagged interactions are serious or life-threatening·4 variations documented
- 11
- Studies
Evidence checked Oct 7, 2026 · newest study 2026
- B
- 3
- C
- 3
- D
- 5
112 community reports across 5 platforms
Coverage
- Effects
- 12
- Helps with
- 4
- Side effects
- 9
- Interactions
- 6 1 high-risk
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Interacts with some medications and supplements — worth checking before combining.See interactions
These are research findings, not promises. A practice does not replace medical treatment.
What does research say?
What studies found for each claimed effect, best evidence first.
12 claims:1 some evidence4 not enough evidence1 not tested in people3 personal stories only3 no benefit found
Wound Healing AccelerationSome evidence it helpsSize of effect: Not known
Some human studies found a benefit. More research could change this.
All 2 studies with a clear result found a benefit. Strongest study: a pooled analysis of several trials.
A pooled analysis of randomized and non-randomized human studies reported that ulcers and dry gangrene resolved, avoiding complete amputation; its analysis of this outcome included 4 people. A 2019 pilot also reported complete resolution in all 10 patients.
Open the Wound Healing Acceleration pageDetoxification SupportNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit. Strongest study: a pooled analysis of several trials.
In two studies, urinary lead decreased from baseline to the last follow-up: the reported mean decreases were 8.40 μg/L (74.40% decrease) and 9.76 μg/g creatinine (58.04% decrease).
Open the Detoxification Support pageBlood Pressure SupportNot enough evidence
Too few or too small studies to know if it works.
All 2 studies with a clear result found a benefit. Strongest study: a pooled analysis of several trials.
Prospective before-and-after studies in an analysis of 24 people reported decreases in systolic blood pressure and heart rate following EDTA treatment.
Open the Blood Pressure Support pageBlood Flow ImprovementNot enough evidence
Too few or too small studies to know if it works.
1 of 2 studies found a benefit; 1 found none. Strongest study: a pooled analysis of several trials.
A pooled analysis of 4 studies reporting ankle-brachial index found an improvement of 0.08 ABI units from baseline in people with conditions including diabetes and peripheral artery disease.
Open the Blood Flow Improvement pageResting Heart Rate ImprovementNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit. Strongest study: a pooled analysis of several trials.
A 2022 analysis reported decreased heart rate after EDTA treatment in prospective before-and-after studies.
Open the Resting Heart Rate Improvement pageInflammation ReductionNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit. Strongest study: an animal study.
In an animal model of chronic kidney disease-related vascular calcification, EDTA decreased NLRP3 expression in the late stage; it also decreased expression in an in vitro model.
Open the Inflammation Reduction pageImmune System SupportOnly personal stories
Only people's own stories online. No study has tested it.
The one study found a benefit.
One proposed explanation is that removing pro-oxidant heavy metals may reduce chronic immune activation and improve immune regulation. This effect was mentioned in 8 of 98 community reports discussing it.
Open the Immune System Support pageCholesterol Level ReductionOnly personal stories
Only people's own stories online. No study has tested it.
The one study found a benefit.
Expert commentary describes a modest reduction in LDL cholesterol levels among patients receiving chelation therapy.
Open the Cholesterol Level Reduction page
Only reported by users, not studied: Mood Improvement, Chronic Pain Reduction, Cognitive Function Improvement, and Anxiety Reduction.
Also studied in people with 4 health conditions
How strong the evidence is in each group. This is research, not a treatment recommendation.
Heart Disease (General)Not enough evidence
Too few or too small studies to know if it works.
1 of 2 studies found a benefit; 1 found none.
A 2022 systematic review of 24 studies, including the TACT trial, reported a reduction in the primary composite endpoint and a small improvement in ABI. Earlier pooled randomized trials disagreed: three larger trials found no benefit, while two small, low-quality trials showed benefit.
Open the Heart Disease (General) pageDiabetes Type 2Not enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
Open the Diabetes Type 2 pageHemochromatosis (Iron Overload)Not tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit.
Deferoxamine or deferasirox is a standard chelation treatment for iron overload in hemochromatosis when phlebotomy is not tolerated.
Open the Hemochromatosis (Iron Overload) pagePost-Cardiac ArrestNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit.
Chelation therapy has been studied specifically in people after myocardial infarction, a subset of post-cardiac-event care; this does not establish an effect after cardiac arrest.
Open the Post-Cardiac Arrest page
What can go wrong
What studies and reports say about its harms and who is most at risk.
- Side effects
Possible: Kidney Function Decrease.
8 more with weak evidence.
- Most at risk if you have
- Hypocalcemia (Low Calcium), Kidney Disease (General), Pregnancy, Bleeding Disorders, Breastfeeding, Long QT Syndrome, and 3 more
- Some trials left out people with
- Allergies (General) and Heart Failure (CHF)
- Serious interactions with
- Calcium
- Reported by users
- Physical Fatigue and Insomnia
General wellness information, not medical advice. If you already do it, talk to a doctor, especially if you take medicines or have a health condition.
The expert view shows every study, dose protocol and source.
Effects
12 listedStart here
Most likely to help, from the evidence we have
- →Wound Healing AccelerationCertaintyMediumSourceRCT2 cited studies
A pooled analysis of randomized and non-randomized human studies reported that ulcers and dry gangrene resolved, avoiding complete amputation; its analysis of this outcome included 4 people. A 2019 pilot also reported complete resolution in all 10 patients.
What the sources found
2 positive · 0 neutral · 0 negativeconfidence 33/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Diabetes
- Diabetes Type 2
- Heart Disease (General)
- Peripheral Artery Disease
Where the evidence comes from
- Article2
Protocol behind this outcome
1 protocolEstimatedWhat the studies reporting this result did.
- Format
- Individual
- Supervision
- Instructor-led
A repeated course
Open Wound Healing AccelerationShow studies (2)
Meta-analysisBpositiven=2435% confidence2022Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review.
EDTA reversed natural cause of disease with healing of ulcers and gangrene avoiding complete amputation.
Top journalPilot studyDpositiven=1030% confidence2019In all those patients, ulcers and dry gangrene completely resolved (Figures 2-3).
Low-quality journalOpen-labelNo control groupCompleters only30% dropped out
Low probability(9)
- →Detoxification SupportCertaintyLowSourceRCT1 cited study · 1 other source
In two studies, urinary lead decreased from baseline to the last follow-up: the reported mean decreases were 8.40 μg/L (SD, 4.29 μg/L) (74.40% decrease) and 9.76 μg/g creatinine (SD, 13.48 μg/g creatinine) (58.04% decrease).
What the sources found
2 positive · 0 neutral · 0 negativeconfidence 55/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Diabetes Type 2
- Heart Disease (General)
- Peripheral Artery Disease
Where the evidence comes from
- Article1
- Community reports1
Open Detoxification SupportShow studies (2)
Meta-analysisBpositiven=2460% confidence2022Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review.
Both studies indicated significant decreases in urinary lead from baseline to last point of follow‐up, with mean decreases of 8.40 μg/L (SD, 4.29 μg/L) (74.40% decrease) and 9.76 μg/g creatinine (SD, 13.48 μg/g creatinine) (58.04% decrease).
-74.4%Large effectTop journalCommunity reportsmoderate effectpositive50% confidenceThis effect was mentioned in 13 of 88 Reddit reports discussing it.
13 mentions - →Blood Pressure SupportCertaintyLowSourceRCT1 cited study · 1 other source
Prospective before-and-after studies in an analysis of 24 people reported decreases in systolic blood pressure and heart rate following EDTA treatment.
What the sources found
2 positive · 0 neutral · 0 negativeconfidence 45/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Diabetes Type 2
- Heart Disease (General)
- Peripheral Artery Disease
Where the evidence comes from
- Article1
- Expert opinion1
Open Blood Pressure SupportShow studies (2)
Meta-analysisBpositiven=2440% confidence2022Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review.
Additional quantitative prospective before/after studies reported significant improvements following EDTA treatment in different outcomes, including decreased heart rate and systolic blood pressure
Top journalExpert opinionpositive50% confidenceReduction in systolic and diastolic blood pressure observed in chelation-treated patients post-MI.
Expert knowledge synthesis - →Blood Flow ImprovementCertaintyLowSourceRCT2 cited studies · 1 other source
A pooled analysis of 4 studies reporting ankle-brachial index found an improvement of 0.08 ABI units from baseline (95% CI, 0.06–0.09) in people with conditions including diabetes and peripheral artery disease.
What the sources found
2 positive · 1 neutral · 0 negativeconfidence 35/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Diabetes
- Diabetes Type 2
- Heart Disease (General)
- Peripheral Artery Disease
Where the evidence comes from
- Article2
- Community reports1
Open Blood Flow ImprovementShow studies (3)
Meta-analysisBpositiven=2460% confidence2022Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review.
A meta‐analysis conducted with 4 studies reporting ankle‐brachial index indicated an improvement of 0.08 (95% CI, 0.06–0.09) from baseline.
MD 0.08 [0.06, 0.09]Top journalStudies disagreePilot studyDneutraln=1025% confidence2019Skin perfusion pressures (mmHg) in the target vascular bed of the affected foot demonstrate a trend towards improvement after edetate disodium infusions (median (IQR): 22 (17-49), 46 (18-69) and 36 (28-43) at baseline, 20 and 40 infusions, respectively, P=0.06).
Low-quality journalMain outcomeOpen-labelNo control groupCompleters only30% dropped outCommunity reportsmoderate effectpositive20% confidenceThis effect was mentioned in 2 of 7 YouTube videos discussing it.
2 mentions - →Resting Heart Rate ImprovementCertaintyLowSourceRCT1 cited study
A 2022 analysis reported decreased heart rate after EDTA treatment in prospective before-and-after studies.
What the sources found
1 positive · 0 neutral · 0 negativeconfidence 40/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Cerebrovascular Disease
- Heart Disease (General)
- Peripheral Artery Disease
Where the evidence comes from
- Article1
Open Resting Heart Rate ImprovementShow studies (1)
Meta-analysisBpositiven=2440% confidence2022Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review.
Additional quantitative prospective before/after studies reported significant improvements following EDTA treatment in different outcomes, including decreased heart rate and systolic blood pressure
Top journal - →Inflammation ReductionCertaintyLowSourceAnimal researchanimal / in-vitro onlynot used for recommendations1 cited study · 1 other source
In an animal model of chronic kidney disease-related vascular calcification, EDTA decreased NLRP3 expression in the late stage; it also decreased expression in an in vitro model.
What the sources found
2 positive · 0 neutral · 0 negativeconfidence 30/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Chronic Kidney Disease
Where the evidence comes from
- Article1
- Community reports1
Why it isn't used for recommendations
Animal or in-vitro evidence only
Open Inflammation ReductionShow studies (2)
Animal studyDpositive35% confidence2025EDTA treatment significantly decreased NLRP3 expression in the late stage in vivo CKD model of vascular calcification, as well as in the in vitro model.
Main outcome75% dropped outCommunity reportsmoderate effectpositive25% confidenceThis effect was mentioned in 2 of 88 Reddit reports discussing it.
2 mentions - →Immune System SupportCertaintyLowSourceAnecdotalnot used for recommendations2 other sources
One proposed explanation is that removing pro-oxidant heavy metals may reduce chronic immune activation and improve immune regulation. This effect was mentioned in 8 of 98 community reports discussing it.
What the sources found
2 positive · 0 neutral · 0 negativeconfidence 45/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Expert opinion1
- Community reports1
Why it isn't used for recommendations
No supporting study on file
Open Immune System SupportShow studies (2)
Expert opinionpositive40% confidenceRemoval of pro-oxidant heavy metals may reduce chronic immune activation and improve immune regulation.
Expert knowledge synthesisCommunity reportsmoderate effectpositive50% confidenceThis effect was mentioned in 8 of 98 community reports discussing it (Reddit 5, Hacker News 3).
8 mentions - →Cholesterol Level ReductionCertaintyLowSourceAnecdotalnot used for recommendations2 other sources
Expert commentary describes a modest reduction in LDL cholesterol levels among patients receiving chelation therapy.
What the sources found
1 positive · 1 neutral · 0 negativeconfidence 38/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Expert opinion1
- Community reports1
Why it isn't used for recommendations
No supporting study on file
Open Cholesterol Level ReductionShow studies (2)
Expert opinionpositive50% confidenceModest reduction in LDL cholesterol levels observed in patients receiving chelation therapy.
Expert knowledge synthesisCommunity reportssubtle effectneutral25% confidenceThis effect was mentioned in 2 of 88 Reddit reports discussing it.
2 mentions - →Cardiovascular Health SupportCertaintyLowSourceAnecdotalnot used for recommendations2 other sources
Expert commentary describes a modest reduction in cardiovascular events among patients treated with chelation therapy after a myocardial infarction. This effect was mentioned in 3 of 7 YouTube videos discussing it.
What the sources found
2 positive · 0 neutral · 0 negativeconfidence 37/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Expert opinion1
- Community reports1
Why it isn't used for recommendations
No supporting study on file
Open Cardiovascular Health SupportShow studies (2)
Expert opinionpositive50% confidenceChelation therapy with EDTA has shown modest reduction in cardiovascular events in post-myocardial infarction patients.
Expert knowledge synthesisCommunity reportsmoderate effectpositive23% confidenceThis effect was mentioned in 3 of 7 YouTube videos discussing it.
3 mentions - →Kidney Health SupportCertaintyLowSourceTheoreticalnot used for recommendations1 cited study · 1 other source
A pilot study did not support improved kidney function: in the seven patients completing 40 infusions, estimated glomerular filtration rate did not change from baseline to infusion 40 (mean ± std 77.8 mL/min/1.73 m^2 ± 17.6 vs. 70.6 mL/min/1.73 m^2 ± 14.5, p = 0.21).
What the sources found
1 positive · 1 neutral · 0 negativeconfidence 25/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Diabetes
- Peripheral Artery Disease
Where the evidence comes from
- Article1
- Community reports1
Why it isn't used for recommendations
Studied, with no positive result
Open Kidney Health SupportShow studies (2)
Pilot studyDneutraln=1025% confidence2019In the seven patients completing 40 infusions, the Modification of Diet in Renal Disease (MDRD) estimated glomerular filtration rate did not change at baseline as compared to infusion 40 (mean ± std 77.8 mL/min/1.73 m^2 ± 17.6 vs. 70.6 mL/min/1.73 m^2 ± 14.5, p = 0.21).
Low-quality journalMain outcomeOpen-labelNo control groupCompleters only30% dropped outCommunity reportsmoderate effectpositive25% confidenceThis effect was mentioned in 2 of 88 Reddit reports discussing it.
2 mentions
Very low probability(2)
- →Physical Endurance IncreaseCertaintyVery lowSourceRCTnot used for recommendations1 cited study
No human finding establishing an increase in physical endurance is reported.
What the sources found
0 positive · 1 neutral · 0 negativeconfidence 50/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Diabetes Type 2
- Heart Disease (General)
- Peripheral Artery Disease
Where the evidence comes from
- Article1
Why it isn't used for recommendations
Studied, with no positive result
Open Physical Endurance IncreaseShow studies (1)
Meta-analysisBneutraln=2450% confidence2022Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review.
Two RCTs conducted in patients experiencing intermittent claudication and in patients with PAD excluded all patients with diabetes at recruitment and found no significant difference in both ABI and pain‐free walking distance comparing repeated EDTA treatment versus placebo.
Top journal - →Analgesic EffectCertaintyVery lowSourceClinicalnot used for recommendations1 cited study
A pilot study of 10 people with diabetes or peripheral artery disease did not support an analgesic effect, although the SF-36 pain score showed a 76.5% median percent improvement (p=0.054).
What the sources found
0 positive · 1 neutral · 0 negativeconfidence 30/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Diabetes
- Peripheral Artery Disease
Where the evidence comes from
- Article1
Why it isn't used for recommendations
Studied, with no positive result
Open Analgesic EffectShow studies (1)
Pilot studyDneutraln=1030% confidence2019There was a 76.5% median percent improvement in the SF-36 pain score (median, interquartile range (IQR) 42.5 (10, 50) vs. 75 (46.3, 78.75), p=0.054) from baseline.
76.5%Large effectLow-quality journalOpen-labelNo control groupCompleters only30% dropped out
Conditions it's used for
Complaints and diagnoses people take it for4 listedThe best we have, but the evidence is still weak
- →Heart Disease (General)CertaintyLowSourceRCT2 cited studies
A 2022 systematic review of 24 studies, including the TACT trial, reported a reduction in the primary composite endpoint and a small improvement in ABI. Earlier pooled randomized trials disagreed: three larger trials found no benefit, while two small, low-quality trials showed benefit.
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Coronary Artery Disease
- Diabetes Type 2
- Heart Disease (General)
- Peripheral Artery Disease
Open Heart Disease (General)Show studies (2)
Systematic reviewBno effectn=28870% confidence2005EDTA chelation therapy for cardiovascular disease: a systematic review.
Systematic review of RCTs; three larger trials showed no benefit, two small trials showed benefit but with low quality.
Pooled RCTsMeta-analysisBn=2460% confidence2022Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review.
Systematic review of 24 studies, including TACT RCT showing reduced primary composite endpoint; meta-analysis of ABI showed small improvement.
Top journal - →Diabetes Type 2CertaintyLowSourceRCT1 cited study
A TACT subgroup analysis found stronger benefit among patients with diabetes (HR 0.59).
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Diabetes Type 2
- Heart Disease (General)
- Peripheral Artery Disease
Open Diabetes Type 2Show studies (1)
Meta-analysisBn=2470% confidence2022Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review.
TACT subgroup analysis showed stronger benefit in patients with diabetes (HR 0.59) and diabetes with PAD (HR 0.52).
HR 0.59Moderate effectTop journal - →Hemochromatosis (Iron Overload)CertaintyLowSourceTheoreticalnot used for recommendations1 other source
Deferoxamine or deferasirox is a standard chelation treatment for iron overload in hemochromatosis when phlebotomy is not tolerated.
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Expert opinion
Why it isn't used for recommendations
No supporting study on file
Open Hemochromatosis (Iron Overload)Show studies (1)
Expert opinion50% confidenceChelation therapy with deferoxamine or deferasirox is a standard treatment for iron overload in hemochromatosis when phlebotomy is not tolerated.
- →Post-Cardiac ArrestCertaintyLowSourceTheoreticalnot used for recommendations1 other source
Chelation therapy has been studied specifically in people after myocardial infarction, a subset of post-cardiac-event care; this does not establish an effect after cardiac arrest.
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Expert opinion
Why it isn't used for recommendations
No supporting study on file
Open Post-Cardiac ArrestShow studies (1)
Expert opinion50% confidenceChelation therapy has been studied specifically in post-MI patients, a subset of post-cardiac-event care.
Side effects
9 listedHighest probability
- →Kidney Function DecreaseCertaintyMediumSourceClinical1 cited study · 1 other source
A systematic review pooling randomized trials in people with coronary artery disease or peripheral artery disease reported increased creatinine, described as kidney toxicity.
What the sources found
0 not observed · 0 unclear · 2 reportedconfidence 58/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Coronary Artery Disease
- Peripheral Artery Disease
Where the evidence comes from
- Article1
- Reference knowledge1
Protocol behind this outcome
1 protocolEstimatedWhat the studies reporting this result did.
- Supervision
- Instructor-led
A repeated course
Open Kidney Function DecreaseShow studies (2)
Systematic reviewBnegativen=28845% confidence2005EDTA chelation therapy for cardiovascular disease: a systematic review.
increased creatinine (kidney toxicity)
Pooled RCTsReference knowledgenegative70% confidenceEDTA is nephrotoxic at high doses or in predisposed individuals; can cause acute tubular necrosis.
Low probability(8)
- →DizzinessCertaintyLowSourceClinical1 cited study
A systematic review pooling randomized trials in people with coronary artery disease or peripheral artery disease reported faintness.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 45/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Coronary Artery Disease
- Peripheral Artery Disease
Where the evidence comes from
- Article1
Protocol behind this outcome
1 protocolEstimatedWhat the studies reporting this result did.
- Supervision
- Instructor-led
A repeated course
Open DizzinessShow studies (1)
Systematic reviewBnegativen=28845% confidence2005EDTA chelation therapy for cardiovascular disease: a systematic review.
faintness
Pooled RCTs - →Mineral ImbalanceCertaintyLowSourceClinical1 cited study
A systematic review pooling randomized trials in people with coronary artery disease or peripheral artery disease reported hypocalcemia.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 45/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Coronary Artery Disease
- Peripheral Artery Disease
Where the evidence comes from
- Article1
Protocol behind this outcome
1 protocolEstimatedWhat the studies reporting this result did.
- Supervision
- Instructor-led
A repeated course
Open Mineral ImbalanceShow studies (1)
Systematic reviewBnegativen=28845% confidence2005EDTA chelation therapy for cardiovascular disease: a systematic review.
hypocalcemia
Pooled RCTs - →Heart Rhythm DisturbanceCertaintyLowSourceReference knowledge1 other source
A pharmacology reference notes that profound calcium depletion caused by chelation can provoke dangerous cardiac rhythm disturbances.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 80/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Reference knowledge1
Open Heart Rhythm DisturbanceShow studies (1)
Reference knowledgenegative80% confidenceProfound chelator-induced calcium depletion can provoke dangerous cardiac rhythm disturbances.
- →Blood Pressure DecreaseCertaintyLowSourceReference knowledge1 other source
A pharmacology reference notes that chelation infusions can cause blood pressure to fall, particularly during administration.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 65/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Reference knowledge1
Open Blood Pressure DecreaseShow studies (1)
Reference knowledgenegative65% confidenceChelation infusions can cause a fall in blood pressure, particularly during administration.
- →Seizure Threshold ReductionCertaintyLowSourceReference knowledge1 other source
A pharmacology reference notes that severe hypocalcemia caused by chelation can lower the seizure threshold.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 65/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Reference knowledge1
Open Seizure Threshold ReductionShow studies (1)
Reference knowledgenegative65% confidenceSevere hypocalcemia from chelation lowers seizure threshold.
- →NauseaCertaintyLowSourceReference knowledge1 other source
Gastrointestinal upset, including nausea, is common with chelation therapy.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 60/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Reference knowledge1
Open NauseaShow studies (1)
Reference knowledgenegative60% confidenceGastrointestinal upset including nausea is common with chelation therapy.
- →Skin Rash / IrritationCertaintyLowSourceReference knowledge1 other source
Chelating drugs can cause allergic skin reactions: rashes are known with deferasirox and DMSA, while deferoxamine and EDTA can cause reactions at the infusion site.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 50/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
Open Skin Rash / IrritationShow studies (1)
Reference knowledgenegative50% confidenceChelating drugs can cause allergic skin reactions: rashes are a known side effect of deferasirox and DMSA, and infusion-site reactions occur with deferoxamine and EDTA.
Background knowledge (no study cited) - →Blood ThinningCertaintyLowSourceReference knowledge1 other source
Bleeding risk differs by chelating drug: deferasirox carries a warning for gut bleeding, and EDTA infusions are often given with the blood thinner heparin.
How big is the effect
No study gave a number we could compare, so the size is not known.
Open Blood ThinningShow studies (1)
Reference knowledgenegative50% confidenceSome chelation drugs raise bleeding risk: deferasirox carries a warning for gut bleeding, and EDTA infusions are often given with the blood thinner heparin.
Background knowledge (no study cited)
Don't do it if
When to skip it or get medical advice first9 listedHighest probability
- →Hypocalcemia (Low Calcium)CertaintyLowSourceReference knowledgeTheoretical
Chelators can bind calcium, potentially worsening low baseline calcium and increasing the risk of seizures and life-threatening cardiac complications.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 85/100
Open Hypocalcemia (Low Calcium)Rationale
Low baseline calcium can worsen when chelators bind calcium, increasing the risk of seizures and life-threatening cardiac complications.
- →Kidney Disease (General)CertaintyLowSourceReference knowledgeTheoretical
Chelated metal complexes are excreted by the kidneys, so pre-existing renal impairment increases the risk of nephrotoxicity and acute kidney injury from chelation.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 80/100
Rationale
Chelated metal complexes are excreted renally; pre-existing renal impairment increases risk of nephrotoxicity and acute kidney injury from chelation.
Subsumes: chronic_kidney_disease; Subsumes: acute_kidney_injury
Open Kidney Disease (General) - →PregnancyCertaintyLowSourceReference knowledgeTheoretical
EDTA crosses the placenta and may bind essential minerals in the fetus, posing a risk of developmental toxicity.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 85/100
Open PregnancyRationale
EDTA crosses the placenta and may chelate essential minerals in the fetus, posing risk of developmental toxicity.
- →Bleeding DisordersCertaintyLowSourceReference knowledgeTheoretical
Chelation therapy can impair coagulation, increasing hemorrhage risk in people with bleeding disorders.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 75/100
Open Bleeding DisordersRationale
Chelation therapy can impair coagulation; patients with bleeding disorders are at increased risk of hemorrhage.
- →BreastfeedingCertaintyLowSourceReference knowledgeTheoretical
EDTA is excreted in breast milk and may impair mineral absorption in the infant.
- →Long QT SyndromeCertaintyLowSourceReference knowledgeTheoretical
Chelator-induced low calcium can prolong cardiac repolarization, adding risk for people who already have a prolonged QT interval.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 75/100
Open Long QT SyndromeRationale
Chelator-induced hypocalcemia can prolong cardiac repolarization, posing additional risk in people with an already prolonged QT interval.
- →PediatricCertaintyLowSourceReference knowledgeTheoretical
Non-medical chelation in children can cause mineral depletion and growth impairment, and its long-term effects are unknown. It should only be used for documented heavy metal poisoning under medical supervision.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 75/100
Open PediatricRationale
Non-medical chelation in children poses risks of mineral depletion, growth impairment, and unknown long-term effects; should only be used for documented heavy metal poisoning under medical supervision.
Low probability(2)
- →Heart Failure (CHF)CertaintyLowSourceReference knowledgeTheoretical
EDTA chelation can cause rapid fluid shifts and low calcium, which may trigger arrhythmias and worsen cardiac function in people with heart failure.
In the trials
2 trials of this practice also left out people with this condition. That does not show harm.
PubMed links (2)
Where the evidence comes from
- Reference knowledge
Confidence
confidence 70/100
Open Heart Failure (CHF)Rationale
EDTA chelation can cause rapid fluid shifts and hypocalcemia, which may precipitate arrhythmias and worsen cardiac function in heart failure patients.
- →Recent Heart Attack (MI)CertaintyLowSourceReference knowledgeTheoretical
Chelation therapy is not initiated immediately after a heart attack because hemodynamic instability and arrhythmias during infusion are concerns.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 70/100
Open Recent Heart Attack (MI)Rationale
Chelation therapy is not initiated immediately post-MI due to hemodynamic instability and risk of arrhythmias during infusion.
Who the trials left out
Some trials of this practice did not take people with these conditions, so the studies say less about them. This is not a warning and does not show harm.3 listed- Allergies (General)left out by 2 trials
PubMed links (2)
PubMed links (2)
Left out by one trial each (1)
- Liver Disease (General)left out by 1 trial
PubMed links (1)
Interactions
Dangerous combinations
Highest severity first
- →SupplementsCalciumTheoreticalLife-threatening
EDTA chelation therapy can cause hypocalcemia. Calcium supplementation during therapy may lead to erratic calcium levels and arrhythmias without medical supervision; IV calcium requires careful management.
- →SupplementsMagnesiumTheoreticalCaution
EDTA binds magnesium, and unsupervised magnesium supplementation during chelation therapy may cause imbalances or mask deficiency symptoms, increasing arrhythmia risk.
- →SupplementsCod Liver OilTheoreticalCaution
Chelation therapy can prolong bleeding time, while cod liver oil has antiplatelet effects; together, these may increase bleeding risk.
- →SupplementsPotassiumTheoreticalCaution
Chelation therapy can cause potassium loss through the kidneys, leading to hypokalemia; potassium depletion increases the risk of cardiac arrhythmias, especially in people with cardiovascular disease.
Weakens or is weakened by
Highest probability
How it works
The mechanisms this practice works through9 listed · 0 established- Bone and tissue Pb, CdMetal mobilization from tissue storesproposed
EDTA creates a concentration gradient that draws metals from deeper tissue stores and bones into circulation for excretion, though this process is slow and requires repeated infusions.
- Brain iron accumulation in globus pallidus internusIron chelationproposed
Deferiprone chelates iron and reduces brain iron overload as measured by MRI R2*.
- Enpep, Osteopontin, MGPAngiogenesisproposed
EDTA increases expression of angiogenesis-related proteins in the aorta.
- Lead and cadmiumMetal chelationproposed
EDTA binds divalent cations such as lead and cadmium, facilitating their renal excretion, potentially reducing metal burden associated with atherosclerosis.
- Lead and cadmiumToxic metal excretionproposed
Edetate disodium chelation increased urinary excretion of lead and cadmium, potentially reducing body stores of vasculotoxic metals.
- NLRP3NLRP3 inflammasome pathwayproposed
EDTA chelation therapy decreases NLRP3 expression and inflammasome formation, reducing SASP production.
- SA-β-gal positive senescent cellsCellular senescenceproposed
EDTA reduces the percentage of senescent cells in calcified aorta, acting as a senomorphic agent.
- Toxic metals (Pb, Cd, Gd)Chelationproposed
EDTA binds divalent and trivalent metals with high stability constants (Pb log K=18, Cd log K=16.9, Gd log K=22), forming stable complexes excreted via urine.
- VSMCsOsteogenic differentiationproposed
EDTA decreases expression of osteogenic markers (RUNX2, OCN, BMP2) and proteins regulating osteogenic differentiation.
Variations
Forms it is offered in. Shown so you can recognise them, not as a guide.4 documentedTypical protocol
7 protocolsEstimatedAcross every study of this practice, whatever the variation.
- Format
- Individual
- Supervision
- Instructor-led
A repeated course
70% of the corpus contributed
EDTA Intensive Limb Salvage Protocol
supervision recommended
EDTA Intensive Limb Salvage Protocol
supervision recommendednot for children,not in pregnancy
EDTA Intravenous Cardiovascular Protocol
supervision recommended
EDTA Intravenous Cardiovascular Protocol
supervision recommendednot for children,not in pregnancy
Studied protocols1 on file
- 1×/week· n=288· A repeated coursePMID 16262904
Low-Dose EDTA Detoxification Infusion
supervision recommended
Low-Dose EDTA Detoxification Infusion
supervision recommendednot for children,not in pregnancy
Oral Deferiprone for Brain Iron Reduction
supervision recommended
Oral Deferiprone for Brain Iron Reduction
supervision recommendednot for children,not in pregnancy
Studied protocols3 on file
- 63 weeks· n=136· A repeated coursePMID 34090847
- 14×/week· n=10· A repeated coursePMID 35956138
- 7×/week· n=31· A repeated coursePMID 41821559
Community experience
Based on 112 public posts from Reddit, Hacker News, YouTube, Phoenix Rising, and Bluesky.
What people report it did
8 outcomes mentioned across 112 public reports. A report often mentions several, so these counts do not add up to the total.
Reported benefits6
- Detoxification Support14 mentions
- Mood Improvement11 mentionsnot studied
- Chronic Pain Reduction11 mentionsnot studied
- Cognitive Function Improvement8 mentionsnot studied
- Anxiety Reduction8 mentionsnot studied
- Immune System Support8 mentions
Reported side effects2
- Physical Fatiguenot studied
- Insomnianot studied
References
12 screened · 11 analysed · 13 listed below
Studies and sources cited on this page. Evidence quality varies — check the grade on each.
- The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review.Health Qual Life Outcomes2024Systematic reviewB
- Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review.J Am Heart Assoc2022Meta-analysisBn=24
- EDTA chelation therapy for cardiovascular disease: a systematic review.BMC Cardiovasc Disord2005Systematic reviewBn=288
- Pharmacokinetics of metal excretion following different doses of sodium EDTA infusion.Metallomics2025Quasi ExperimentalCn=10
- Cardiac iron overload evaluation in thalassaemic patients using T2* magnetic resonance imaging following chelation therapy: a multicentre cross-sectional study.Hematol Transfus Cell Ther2023Observational CohortCn=136
- Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy.J Clin Med2022Observational CohortCn=10
- Association Between Iron Overload and Glucose Metabolism in Children and Youth with Transfusion-Dependent Beta Thalassemia: The Role of Chelation Therapy.Mediterr J Hematol Infect Dis2026Observational CohortDn=31
- Targeted chelation therapy decreases NLRP3 expression by vascular cells and acts as senomorphic in chronic kidney disorder induced vascular calcification.Int J Immunopathol Pharmacol2025Animal studyD
- D-Penicillamine-Induced Stevens-Johnson Syndrome in a Patient with Gold Cyanide Intoxication: A Case Report.Clin Cosmet Investig Dermatol2024Case reportDn=1
- Evaluation on curative effects of ethylene diamine tetra-acetic acid chelation therapy in treating with atherosclerotic cardiovascular disease: A protocol for systematic review and meta-analysis.Medicine (Baltimore)2020Narrative reviewD
Show all 13 references
- Limb Preservation Using Edetate Disodium-based Chelation in Patients with Diabetes and Critical Limb Ischemia: An Open-label Pilot Study.2019Pilot studyDn=10
- Expert knowledge synthesis
- Background knowledge (no study cited)